Document is current
Any future updates will be listed below
-
Authors
Kratzmeier, Christina
Singh, Sasha
Asiedu, Emmanuel B.
Webb, Tonya J. https://orcid.org/0000-0003-3086-6414
-
Funding
Funding for this research was provided by:
National Institutes of Health (P30CA134274)
National Institutes of Health (R25GM113262)
- License Information
-
More Information
Article History
Accepted: 26 November 2022
First Online: 16 December 2022
Declarations
:
: This article was supported by funds through the National Cancer Institute—Cancer Center Support Grant (CCSG)—P30CA134274, NIH NIGMS R25GM113262, and funds through the Maryland Department of Health’s Cigarette Restitution Fund Program—CH-649-CRF.
: T.J.W. is the CEO of WebbCures, LLC, co-founded IMMUNE3D, Screen Therapeutics, and is on the scientific advisory board for Immunaccel Labs. The other authors, C.K., S.S., and E.B.A. declare that they have no conflicts of interest that might be relevant to the contents of this article.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: CK, SS, EAB, and TJW wrote and edited the manuscript. All authors have read and agreed to the published version of the manuscript.
